Chief Medical Officer resigns from Cadrenal Therapeutics
Cadrenal Therapeutics entered into a separation agreement with CMO James Ferguson III following his voluntary resignation for July 2026. This leadership change may impact the biotech firm's clinical development strategies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day